Last $27.86 USD
Change Today -0.06 / -0.21%
Volume 129.3K
QDEL On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 5:10 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Open
$27.91
Previous Close
$27.92
Day High
$28.12
Day Low
$27.64
52 Week High
01/15/14 - $32.24
52 Week Low
04/24/14 - $19.21
Market Cap
958.7M
Average Volume 10 Days
139.6K
EPS TTM
$-0.29
Shares Outstanding
34.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia RSV and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

572 Employees
Last Reported Date: 02/27/14
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $509.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $313.2K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $307.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Business Development...
Total Annual Compensation: $329.0K
Compensation as of Fiscal Year 2013.

quidel corp (QDEL) Key Developments

Kenneth J. Widder Joins Quidel Corporation's Board of Directors

Quidel Corporation announced that Kenneth J. Widder, M.D. has agreed to join Quidel's Board of Directors, effective immediately. Quidel's Board has been expanded to eight members. Dr. Widder has more than thirty years of experience working with biomedical companies and has been a General Partner with Latterell Venture Partners since 2007. Dr. Widder is also a member of the Board of Directors of Evoke Pharma Inc., Meritage Pharma Inc., and Naurex Inc.

Quidel Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Announces Impairment Charges for the Third Quarter Ended September 30, 2014; Provides Effective Tax Rate Guidance for Full Year of 2014

Quidel Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $40,857,000 compared to $33,539,000 in the third quarter of 2013, the increase in revenue was due to greater sales of Infectious Disease products in the third quarter of 2014 and growth across all categories, as well as a $2.8 million increase in grant revenue. Net loss was $5,767,000 or $0.17 per share, compared to net loss of $4,361,000 or $0.13 per share, for the third quarter of 2013. On a non-GAAP basis, the company reported net loss of $0.5 million, or $0.01 per share, compared to net loss of $0.5 million, or $0.02 per share, for the third quarter of 2013. Operating loss was $10,121,000 compared to $5,795,000 a year ago. Loss before taxes was $10,345,000 compared to $6,156,000 a year ago. Adjusted net loss was $502,000 or $0.01 per diluted share compared to adjusted net loss of $519,000 or $0.02 per diluted share a year ago. In the third quarter, operating activities provided $200,000 of cash, and purchase of property and equipment was $1.9 million in the quarter. For the nine months, the company reported total revenues of $119,018,000 compared to $125,240,000 for the same period a year ago. The decrease in revenue was primarily driven by softer demand for Infectious Disease products in the first quarter due to a weaker respiratory disease season in 2014, relative to the same period in 2013. Net loss was $14,187,000 or $0.41 per share, compared to net income of $6,251,000 or $0.13 per share for the same period a year ago. On a non-GAAP basis, the company reported net loss of $1.0 million, or $0.03 per diluted share, compared to net income of $14.4 million, or $0.41 per diluted share, for the first nine months of 2013. Operating loss was $22,123,000 compared to operating profit of $4,607,000 a year ago. Loss before taxes was $23,078,000 compared income before taxes was $3,523,000 a year ago. Adjusted net loss was $994,000 or $0.41 per diluted share compared to adjusted net income of $14,384,000 or $0.18 per diluted share a year ago. For the third quarter ended September 30, 2014, the company reported amortization of intangibles was $3,931,000 against $4,278,000 a year ago. The impairment loss relates to the company's Stella (Bobcat) technology and associated assets, and includes the write-off of in-process Research and Development, development software and the associated manufacturing line. Impairment loss was $3,558,000 against $3,558,000 a year ago. For the full year of 2014, the company provides effective tax rate of 37%.

Quidel Receives FDA Clearance for its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus

Quidel Corporation announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus (HAdV) viral DNA isolated from nasal swab and nasopharyngeal swab specimens. Adenovirus outbreaks can occur throughout the year, but are more common from late winter to early summer. Adenovirus infections are seldom life-threatening, however, these viruses can cause several illnesses and symptoms, such as colds, sore throat, bronchitis, pneumonia, diarrhea, pink eye and fever. Severe complications from adenovirus infection can present in infants and people with weakened immune systems. According to the Centers for Disease Control and Prevention (CDC), adenovirus is spread through: close personal contact, such as shaking hands or touching, the air by coughing or sneezing, and touching contaminated objects or surfaces. Some people infected with adenovirus can have ongoing infections without any symptoms, shedding the virus for months or even years. Quidel's Lyra Adenovirus Assay is part of the exciting new Lyra brand of ready-to-use, molecular PCR reagent kits specifically designed to be compatible with a laboratory's existing thermocycler. The Lyra reagent kits provide attractive features, including a short time to result, ready-to-use master mix, and refrigerated, non-frozen storage of key reagents, as well as other benefits. The new Lyra Adenovirus Assay augments the growing menu of other FDA-cleared assays on the Lyra platform. The quickly expanding menu of Lyra-based infectious disease products provides healthcare workers with the flexibility needed to meet the specific needs of the clinical laboratory, especially as testing needs shift for specific pathogens with overlapping and variable seasonality. The Lyra assays yield highly sensitive, quantitative PCR results within 75 minutes. Quidel now offers FDA-cleared Lyra assays for a dozen different infectious agents, including eight molecular tests for respiratory disease (Strep A, Strep C+G, Influenza A, Influenza B, human metapneumovirus (hMPV), respiratory syncytial virus (RSV), and adenovirus (HAdV)) and four other PCR assays for other serious infectious disease pathogens (herpes simplex virus (HSV) types 1 and 2, varicella zoster virus (VZV) and C. difficile).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $27.86 USD -0.06

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $72.84 USD -0.45
Ion Beam Applications €13.90 EUR +0.05
Luminex Corp $18.50 USD -0.11
Meridian Bioscience Inc $16.45 USD -0.14
OraSure Technologies Inc $9.01 USD -0.22
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.